Data completeness
2/8 — Basic
Ruxolitinib (ruxolitinib) by Incyte is janus kinase inhibitors [moa].
Drug data last refreshed 46m ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Ruxolitinib is an oral small-molecule Janus Kinase (JAK) inhibitor developed by Incyte. It modulates immune signaling pathways by inhibiting JAK enzymes, which are central to inflammatory and hematologic disease mechanisms. The drug is currently in pre-launch phase, indicating active preparation for market entry.
Pre-Launch
Pre-launch status signals active team building across commercial, medical, and operations functions; significant career opportunity for professionals willing to invest in product launch execution.
Mechanism of Action
Janus Kinase Inhibitors
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
A Study to Compare Elritercept to Placebo in Adults With Myelofibrosis and Anemia Who Are Taking Ruxolitinib
Started Aug 2026
324 enrolled
MyelofibrosisAnemia
Comparing Momelotinib and Ruxolitinib in People With Untreated Myelofibrosis and Low Blood Cell Counts
Started Aug 2026
268 enrolled
MyelofibrosisMyelofibrosis (MF)
Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)
Started Aug 2026
15 enrolled
Myelofibrosis
Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE)
Started Jul 2026
16 enrolled
Immune Effector Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (IEC-HS)
A Phase 3 Study of Pelabresib (DAK539) and Ruxolitinib in Myelofibrosis (MF)
Started Jun 2026
460 enrolled
Primary Myelofibrosis (PMF)Post-polycythemia Vera Myelofibrosis (PPV-MF)Post-essential Thrombocythemia Myelofibrosis (PET-MF)
Worked on Ruxolitinib at Incyte? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.